Antiinflammatory, Analgesic, NSAID-Non Steroidal Antiinflammatory Drug, Protein bound drug, Ulcerogenic drug, Injectable NSAID
Carpaquin™, Carprieve™, Norocarp®, Novox®, Rimadyl®, Rovera®, TruProfen™, Vetprofen®, quellin™
Non steroidal anti-inflammatory drug
- Contraindicated in patients with known sensitivity to this type of drug.
- Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with renal, cardiovascular, and/or hepatic dysfunction.
- The use of parenteral fluids during surgery should be considered to reduce the potential risk of renal complications when using NSAIDs perioperatively.
- Carprofen is not recommended for use in dogs with bleeding disorders (e.g., Von Willebrand’s disease), as safety has not been established in dogs with these disorders.
- The safe use of carprofen in animals less than 6 weeks of age, pregnant dogs, dogs used for breeding purposes, or in lactating bitches has not been established.
- Contraindicated in dogs with bleeding disorders, GI ulcers, patients with liver disease or pre existing renal impairment.
- The safe use of Rimadyl in animals less than 6 weeks of age, pregnant dogs, dogs used for breeding purposes, or in lactating bitches has not been established.
- Not labeled for use in cats.
- Gastrointestinal: Vomiting, diarrhea, constipation, inappetence, melena, hematemesis, gastrointestinal ulceration, gastrointestinal bleeding, pancreatitis.
- Hepatic: Inappetence, vomiting, jaundice, acute hepatic toxicity, hepatic enzyme elevation, abnormal liver function test(s), hyperbilirubinemia, bilirubinuria, hypoalbuminemia. Approximately one-fourth of hepatic reports were in Labrador Retrievers.
- Neurologic: Ataxia, paresis, paralysis, seizures, vestibular signs, disorientation.
- Urinary: Hematuria, polyuria, polydipsia, urinary incontinence, urinary tract infection, azotemia, acute renal failure, tubular abnormalities including acute tubular necrosis, renal tubular acidosis, glucosuria.
- Behavioral: Sedation, lethargy, hyperactivity, restlessness, aggressiveness.
- Hematologic: Immune-mediated hemolytic anemia, immune-mediated thrombocytopenia, blood loss anemia, epistaxis.
- Dermatologic: Pruritus, increased shedding, alopecia, pyotraumatic moist dermatitis (hot spots), necrotizing panniculitis/vasculitis, ventral ecchymosis.
- Immunologic or hypersensitivity: Facial swelling, hives, erythema.
- In rare situations, death has been associated with some of the adverse reactions listed above.
- Hepatocellular damage, jaundice and/or renal disease can occur and dogs with pre existing conditions and geriatric dogs seem to be at greater risk. Labrador Retrievers have been associated with 1/3 of the cases of hepatic syndrome.
- Drug compatibility should be monitored closely in patients requiring additional therapy. Such drugs commonly used include cardiac, anticonvulsant and behavioral medications.
- Contraindicated with corticosteroids as increased risk for side effects may result.
- Side effect risk increases with dehydration and with the use of diuretics.
NSAID-Non Steroidal Antiinflammatory Drug
- Contraindicated with concurrent use of other NSAIDs because it may increase the risk of side effects.
Protein bound drug
- May displace other highly protein bound drugs resulting in increased serum levels and duration of action.
- Increased risk for GI ulceration is additive with ulcerogenic drugs concurrently.
- Use in caution in patients in cardiac failure-may reduce diuretic effects of furosemide.
- Use extreme caution when using methotrexate concurrently as serious toxicity has occurred when used with NSAIDs
- There may be an increased risk for hepatotoxicity secondary to carprofen metabolites.
Veterinary – General
- Tablets – 25, 75 and 100 mg caplets in btls of 4, 30, 60 or 180; Rimadyl®, in bottles of 30 tablets; TruProfen™ and in btls of 30, 60 and 180; Novox®, Carprieve™ (formerly Norocarp®), in bottles of 60 and 240 caplets: Vetprofen® and in bottles of 72 and 210 caplets; Carpaquin™. Approved for dogs. Chewable tablets – 25, 75 and 100 mg tablets in bottles of 7, 30, 60 or 180; Rimadyl®, in bottles of 30 tablets; Quellin™, in bottles of 30, 60 or 180 tablets; Rovera®. Approved for use in dogs. Injectable – 50 mg/mL in 20 mL btls; Rimadyl® Injectable. Approved for dogs.